Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer

Johanna C. Bendell, Heinz‐Josef Lenz, Theresa Ryan, Bassel F. El‐Rayes, John L. Marshall, Manuel Modiano, Lowell L. Hart, C. Daniel Kingsley, Thomas J. George, Daisuke Nakashima,

Investigational New Drugs · 2014 · 13 citations · 22 references

Concepts

References

22